Follow this blog:
RSS

The Morning Briefing: Drug development

By | June 25, 2012, 10:17 PM PDT

“The Morning Briefing” is SmartPlanet’s daily roundup of must-reads from the web. This morning we’re reading about drug development and innovation.

1.) Profit from the next innovative class of drugs. Innovation in drug development comes in waves. Important discoveries often lead to not just one drug, but a multitude. Understanding the biology of a disease, for instance, can often lead to multiple drug candidates, sometimes improving on each other and other times just rehashing the same mechanism.

2.) FDA delays decision on Pfizer, Bristol-Myers drug. Shares of Pfizer Inc. and Bristol-Myers Squibb Co. fell Monday after federal regulators unexpectedly delayed for a second time a decision on whether to approve the companies’ highly touted experimental anticlotting drug Eliquis.

3.) Experimental insulin drug prevents low blood sugar. An experimental insulin drug prevented low blood sugar among diabetic patients more often than a popular drug on the market, a new study finds.

4.) Pfizer’s internal emails reveal it fudged info about its blockbuster painkiller. Recently released internal emails reveal that Pfizer Inc.’s employees misled consumers about dangers tied to its hugely popular arthritis drug Celebrex.

5.) Drugmakers seek EU deal to keep supplies flowing. The head of Europe’s drug industry has written to EU leaders ahead of their summit this week seeking major concessions to help keep supplies of medicines flowing to crisis-hit countries like Greece and Spain.

Image credit: Derek Gravy

Related:

Start your week smarter with our weekly e-mail newsletter. It's your cheat sheet for good ideas. Get it.

Charlie Osborne

About Charlie Osborne

Charlie Osborne is a contributing editor for SmartPlanet.

Charlie Osborne

Charlie Osborne

Contributing Editor

Charlie Osborne is a freelance journalist and graphic designer based in London. In addition to SmartPlanet, she also writes the iGeneration column for business technology website ZDNet. She holds degrees in medical anthropology from the University of Kent.

Follow her on Twitter.

Charlie Osborne

Charlie Osborne

Charlie Osborne does not have financial holdings that would influence how or what she covers.

She writes for SmartPlanet and is not an employee of CBS.

If you liked this, don't miss...
1
Comments

Join the conversation!

Follow via:
RSS
0 Votes
+ -
Are those drugs really necessary?
Why is it that for every ailment there is a drug and for every drug an imaginary ailment can be determined to fit a drug?
Changes in "lifestyle" such as diet and some sunshine and comparably cheaper supplements would substantially reduce the need for most of those drugs.
An added benefit would be no side effects.
Some statistics even claim that 97% (yes 97%) of open heart surgery could be eliminated by a mere change in lifestyle choices.
Posted by kwickset@...
26th Jun
Join the conversation
Formatting +
BB Codes - Note: HTML is not supported in forums
  • [b] Bold [/b]
  • [i] Italic [/i]
  • [u] Underline [/u]
  • [s] Strikethrough [/s]
  • [q] "Quote" [/q]
  • [ol][*] 1. Ordered List [/ol]
  • [ul][*] · Unordered List [/ul]
  • [pre] Preformat [/pre]
  • [quote] "Blockquote" [/quote]

Join the SmartPlanet community and join the conversation! Signing up is fast and free. Don't wait -- we want to hear your opinion!